Sinclair IS Pharma plc

(formerly Sinclair Pharma plc)

Admission of Shares, Change of Name and Change of Registered Address

Further to the announcement by the Company on 03 May 2011 confirming the results of the General Meeting, the Board of Sinclair IS Pharma plc ("Sinclair IS Pharma" or the "Company") can now confirm that 139,834,683 New Ordinary Shares have today been admitted to the Official List and to trading on the London Stock Exchange's main market for listed securities. Dealings in the New Ordinary Shares on the London Stock Exchange's main market commenced at 8.00 a.m. this morning.

The 380,814,243 Ordinary Shares in issue comprise 240,979,560 Ordinary Shares representing Ordinary Shares in issue prior to the Merger and 139,834,683 New Ordinary Shares issued in connection with the Merger.

The Company has applied to the UK Listing Authority to cancel admission of all its Ordinary Shares (including the New Ordinary Shares) to listing on the Official List and to the London Stock Exchange to cancel the trading of all of its Ordinary Shares (including the New Ordinary Shares) on the London Stock Exchange's main market for listed securities and has applied to the London Stock Exchange for admission of the Ordinary Shares (including the New Ordinary Shares) to trading on AlM. Accordingly, it is anticipated that the last day of dealings of the Ordinary Shares (including the New Ordinary Shares) on the London Stock Exchange's main market for listed securities will be 3 June 2011. Cancellation of admission to listing of the Ordinary Shares (including the New Ordinary Shares) on the Official List and to trading on the London Stock Exchange's main market for listed securities is expected to take effect at 8:00 a.m. on 6 June 2011. AlM Admission is expected to take place and dealings in Ordinary Shares (including the New Ordinary Shares) are expected to commence on AlM at 8:00 a.m. on 6 June 2011.

Upon admission of the New Sinclair Pharma Shares to listing on the Official List, the Company will change its name from Sinclair Pharma plc to Sinclair IS Pharma plc. The Company's shares will trade under the new name with effect from 8.00 a.m. on 23 May 2011. In order to reflect the change to the new name, the Company is changing its website address to www.sinclairispharma.com.

The Company's registered address has changed to Whitfield Court, 30-32 Whitfield Street, London, W1T 2RQ with immediate effect.

Terms defined in the Prospectus of the Company dated 8 April 2011 shall have the same meaning when used in this announcement.

For further information, please contact:

Sinclair IS Pharma plc Tel: +44 (0)1483 410 600

Christopher Spooner, CEO

Matthew Hall, CFO

Singer Capital Markets Limited Tel: +44 (0)20 3205 7500

Shaun Dobson Claes Spång

Financial Dynamics Tel: +44 (0)20 7831 3113

Ben Atwell

Stephanie Cuthbert